956901-23-8

Usage

Uses

Used in Pharmaceutical Industry:
(R)-N-(4-(1-aminoethyl)-2,6-difluoro-phenyl)-methanesulfonamide hydrochloride is used as a chemical intermediate for the development of new drugs due to its unique structural features and potential therapeutic effects. Its ability to target specific biological pathways makes it a promising candidate for creating medications to treat a range of diseases.
Used in Preclinical Research:
In the field of preclinical research, (R)-N-(4-(1-aminoethyl)-2,6-difluoro-phenyl)-methanesulfonamide hydrochloride serves as a test compound to evaluate its efficacy and safety in treating various medical conditions. (R)-N-(4-(1-aminoethyl)-2,6-difluoro-phenyl)-methanesulfonamide hydrochloride's interactions with different biological targets can provide valuable insights into its potential applications in drug development.
Used in Drug Design and Synthesis:
(R)-N-(4-(1-aminoethyl)-2,6-difluoro-phenyl)-methanesulfonamide hydrochloride is utilized as a key component in the design and synthesis of novel pharmaceuticals. Its structural properties allow for the creation of new drug candidates that can potentially address unmet medical needs or improve upon existing treatments.
Used in Drug Delivery Systems:
Similar to gallotannin, (R)-N-(4-(1-aminoethyl)-2,6-difluoro-phenyl)-methanesulfonamide hydrochloride may also be employed in drug delivery systems to enhance its bioavailability, delivery, and therapeutic outcomes. By incorporating (R)-N-(4-(1-aminoethyl)-2,6-difluoro-phenyl)-methanesulfonamide hydrochloride into various carriers, such as organic or metallic nanoparticles, its effectiveness in targeting specific diseases can be improved.

Upstream product

• 956901-21-6 N-(4-acetyl-2,6-difluorophenyl)methanesulfonamide 
• 886842-80-4 N-(4-bromo-2,6-difluorophenyl)methanesulfonamide 
• 67567-26-4 4-bromo-2,6-difluoroaniline 
• 956901-22-7 N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]methanesulfonamide 
• 1005172-60-0 C₁₃H₁₈F₂N₂O₃S₂ 

Downstream Products

• 956901-20-5 2-(6-tert-butylpyridin-3-yl)-N-((1R)-1-{3,5-difluoro-4-[(methylsulfonyl)amino]phenyl}ethyl)-2-methylcyclopropanecarboxamide 
• 958327-94-1 ((1R)-1-{3,5-difluoro-4-[(methylsulfonyl)amino]phenyl}ethyl)-6-(trifluoromethyl)quinoline-2-carboxamide 
• 958328-53-5 N-((1R)-1-{3,5-DIFLUORO-4-[(METHYLSULFONYL)AMINO]PHENYL}ETHYL)-7-(TRIFLUOROMETHYL)QUINOLINE-3-CARBOXAMIDE 
• 1202643-08-0 (R)-N-[1-(3,5-difluoro-4-methanesulfonylarmino-phenyl)-ethyl]-2-(4-t-butylbenzyl)-thiazole-4-amide 

Relevant academic research and scientific papers

METHOD FOR PREPARING (R)-N-[4-(1-AMINO-ETHYL)-2,6-DIFLUORO-PHENYL]-METHANESULFONAMIDE

Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliar

CHIRAL RESOLUTION METHOD OF N-[4-(1-AMINOETHYL)-PHENYL]-SULFONAMIDE DERIVATIVES

The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O′-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O′-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.

AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME

Compounds are disclosed that have a formula represented by the following: Formula (I). The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.

CYCLOPROPANECARBOXAMIDE COMPOUND

This invention relates to novel substituted N-(N-sulfonylaminoarylmethyl)cyclopropanecarboxamide compound and to their use in therapy. This invention provides 2-(6-tert-butylpyridin-3-yl)-N-((1R)-1-{3,5-difluoro-4-[(methylsulfonyl)amino]phenyl}ethyl)-2-me